Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dyax, a developer of novel biotherapeutics for unmet medical needs, has treated first patient in a randomized, double-blind, placebo-controlled Phase 2 trial to investigate the safety and efficacy of ecallantide in patients with angiotensin converting enzyme (ACE) inhibitor-induced angioedema.
Subscribe to our email newsletter
The trial aims to compare the effectiveness and safety of conventional therapy treatment plus ecallantide to conventional therapy treatment plus placebo in 176 patients recruited at 40 US clinical sites.
Dyax president and CEO Gustav Christensen said they believe that ecallantide’s application extends beyond HAE into multiple inflammatory disorders, and their ACE inhibitor-induced angioedema Phase 2 study marks an important step toward realizing this potential.
"We look forward to seeing results of this study, which are currently anticipated in the second half of 2012," Christensen said.